Candel Therapeutics, Inc. ( (CADL) ) has released its Q4 earnings. Here is a breakdown of the information Candel Therapeutics, Inc. presented to its investors.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to treat cancer, leveraging novel adenovirus and herpes simplex virus gene constructs.
In its latest earnings report, Candel Therapeutics announced positive outcomes from clinical trials, particularly highlighting the success of its CAN-2409 therapy in prostate and pancreatic cancers. The company also shared its financial results for the fourth quarter and full year 2024, alongside strategic developments.
Key highlights include the successful phase 3 trial of CAN-2409 in localized prostate cancer, showing a significant reduction in recurrence risk, and promising phase 2a results in pancreatic cancer with notable survival benefits. The company is preparing for a Biologics License Application for CAN-2409 in prostate cancer, expected in late 2026. Financially, Candel reported a decrease in research and development expenses and a net loss increase due to changes in warrant liability.
Looking ahead, Candel is focused on advancing its pipeline, with upcoming data releases expected in 2025 for its trials in lung cancer and glioma. The company remains well-funded, with cash reserves projected to support operations into early 2027, as it continues to explore new therapeutic avenues and regulatory approvals.